PGDH (9T2) Rabbit Monoclonal Antibody
Konjugasyon: Unconjugated
Recombinant rabbit monoclonal antibody
Uygulama
Reaktivite
Human
Gen Adı
HPGD
Saklama
Aliquot and store at -20°C (valid for 12 months). Avoid freeze/thaw cycles.
Özet
| Ürün Adı | PGDH (9T2) Rabbit Monoclonal Antibody |
| Açıklama | Recombinant rabbit monoclonal antibody |
| Konak | Rabbit |
| Reaktivite | Human |
| Konjugasyon | Unconjugated |
| Modifikasyon | Unmodified |
| İzotip | IgG |
| Klonalite | Monoclonal |
| Form | Liquid |
| Konsantrasyon | Unconjugated |
| Saklama | Aliquot and store at -20°C (valid for 12 months). Avoid freeze/thaw cycles. |
| Nakliye | Ice bags. |
| Tampon | Supplied in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40%Glycerol, 0.01% New type preservative N and 0.05% protective protein. |
| Saflaştırma | Affinity purification |
Antijen Bilgisi
| Gen Adı | HPGD |
| Alternatif İsimler | 15-PGDH; Hpgd; PGDH; PGDH1; PHOAR1; SDR36C1; |
| Gen Kimliği | 3248 |
| SwissProt Kimliği | P15428 |
| İmmünojen | Recombinant protein of human Prostaglandin dehydrogenase 1 |
Uygulama
| Uygulama | WB,IHC,ICC/IF,FC |
| Seyreltme Oranı | WB 1:1000-1:5000,IHC 1:500-1:2000,ICC/IF 1:100-1:200,FC 1:50-1:100 |
| Moleküler Ağırlık | 29kDa |
Araştırma Alanı
| Immunology |
Arka Plan
| Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. Primary enzyme catalyzing the conversion of hydroxylated arachidonic acid species to their corresponding oxidized metabolites (Probable). Prostaglandin inactivation, catalyzes the first step in the catabolic pathway of the prostaglandins. Contributes to the regulation of events that are under the control of prostaglandin levels (PubMed:15574495, PubMed:16828555, PubMed:8086429). Catalyzes the NAD- dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4 (PubMed:10837478). Converts 11(R)-HETE to 11-oxo-5,8,12,14-(Z,Z,E,Z)- eicosatetraenoic acid (ETE) (PubMed:21916491). Has hydroxylated docosahexaenoic acid metabolites as substrates (PubMed:25586183). Converts resolvins E1, D1 and D2 to their oxo products which represents a mode of resolvins inactivation and stabilizes their anti-inflammatory actions (PubMed:16757471, PubMed:22844113). |
